Phase 2 Myeloma Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• You have been diagnosed with multiple myeloma (a type of blood cancer affecting plasma cells in the bone marrow), confirmed by standard medical tests
• Your myeloma is currently active and measurable through blood or urine tests showing abnormal protein levels
• Your myeloma cells have a specific genetic change called the (11;14) translocation, confirmed by a laboratory test called FISH or chromosomal analysis
• Your blood counts are at acceptable levels: white blood cells (neutrophils) at least 1.5, platelets at least 75, and hemoglobin at least 8.0 g/dL within the past 3 weeks
• Your kidneys are working well enough, with a kidney function score of at least 30 mL/minute
• Your liver test results (bilirubin, AST, ALT) are at or near normal levels
• Your blood potassium level is within the normal range (3.0–5.5 mEq/L)
• You are generally able to carry out some daily activities (your doctor has rated your overall health status as 0, 1, or 2 on a standard scale)
• You have already received at least one prior treatment for multiple myeloma, which must have included a proteasome inhibitor, lenalidomide, and a steroid medication
• Your myeloma has been confirmed to be getting worse (progressing) according to standard medical guidelines
• If you are a woman who could become pregnant, you must be willing to use two forms of birth control at the same time, starting at least 28 days before treatment, and agree to regular pregnancy tests; contraception must continue for 3 months after treatment ends
• If you are a man, you must agree to use a condom during sexual contact with a woman who could become pregnant, even if you have had a vasectomy

Who may not be able to join:

• You have previously had a bad reaction or intolerance to any of the medications used in this trial
• You have certain other serious conditions, including a protein build-up disorder (amyloidosis), a rare nerve and organ disorder called POEMS syndrome, HIV infection, active hepatitis B or C, serious heart problems (such as uncontrolled chest pain, severe irregular heartbeat, a heart attack within the last 6 months, or significant heart failure), major surgery in the last 4 weeks, a serious active infection requiring IV treatment in the last 2 weeks, uncontrolled diabetes or high blood pressure in the last 2 weeks, or any other condition your doctor feels would make participation unsafe
• You have had another active cancer in the past 3 years, unless it was fully treated and removed with no signs of return, and is unlikely to affect your survival during the study
• You previously had a bone marrow transplant using donor cells and still have signs of graft-versus-host disease (where the donor cells are attacking your body)
• You are currently pregnant or breastfeeding
• You have a known allergy to any of the study medications or their ingredients
• You received an anti-CD38 antibody treatment (such as daratumumab or isatuximab) within the last 3 weeks
• You were previously treated with an anti-CD38 antibody (daratumumab or isatuximab) and your myeloma did not show at least a minimal response to it
• You have previously been treated with venetoclax (one of the drugs being studied)
• You received chemotherapy, high-dose steroids, immunotherapy, or certain other cancer treatments within the last 3 weeks before starting the study
• You received extensive radiation therapy within the last 28 days (targeted local radiation may still be acceptable — confirm with trial site)
• You participated in another experimental drug study within the last 28 days
• You have taken certain medications that affect how the body processes drugs (called CYP3A inhibitors or inducers) within the last 7 days
• You have eaten grapefruit, Seville oranges (including marmalade), or star fruit within 3 days before starting the study drugs
• You are currently taking certain medications including warfarin (a blood thinner) or other drugs that may interact with the study medications (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.